BioNTech says 90% of 2024 revenues will accrue at end of year
By Ludwig Burger
FRANKFURT (Reuters) -Germany’s BioNTech, whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year.
BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros.
“BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024,” the company added.
First quarter revenues plunged to 188 million euros from 1.28 billion a year earlier. The biotech firm posted a quarterly net loss of 315 million euros, compared with a profit of 502 million a year earlier.
Partner Pfizer said last week it still expects $8 billion in combined 2024 sales of its COVID-19 products, $5 billion of which from the Comirnaty-branded COVID-19 vaccine.
($1 = 0.9287 euros)
(Reporting by Ludwig Burger, Editing by Rachel More)
Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.